mhurhangee/ep-ind-claims huggingface dataset:
A method of preparing at least one doped silicon single crystal comprising the steps of: a) providing a melt material comprising silicon into a continuous Czochralski crystal growth apparatus having an inner growth chamber and an outer melt chamber; b) delivering a dopant to said melt material, wherein the dopant is gallium, indium, or aluminium, wherein the dopant is delivered based on a model employed to predict dopant concentration within the melt material in the inner growth chamber of the crystal growth apparatus, wherein the model predicts an amount of evaporation of said dopant from the melt material over time; c) providing a seed crystal into said melt material, wherein said melt material is in molten form; d) growing a doped silicon single crystal by providing a silicon container to the outer melt chamber of the crystal growth apparatus and withdrawing said seed crystal from said melt material, wherein additional melt material is provided to the crystal growth apparatus during the growing step, further wherein said container defines a center, threaded cavity with an amount of dopant contained therein and comprises a threaded plug configured to be secured in a portion of said threaded cavity; wherein the method comprises sequentially preparing a series of doped silicon single crystals and wherein said delivering step comprises delivering said dopant into the melt material via one or more doping events. a) providing a melt material comprising silicon into a continuous Czochralski crystal growth apparatus having an inner growth chamber and an outer melt chamber; b) delivering a dopant to said melt material, wherein the dopant is gallium, indium, or aluminium, wherein the dopant is delivered based on a model employed to predict dopant concentration within the melt material in the inner growth chamber of the crystal growth apparatus, wherein the model predicts an amount of evaporation of said dopant from the melt material over time; c) providing a seed crystal into said melt material, wherein said melt material is in molten form; d) growing a doped silicon single crystal by providing a silicon container to the outer melt chamber of the crystal growth apparatus and withdrawing said seed crystal from said melt material, wherein additional melt material is provided to the crystal growth apparatus during the growing step, further wherein said container defines a center, threaded cavity with an amount of dopant contained therein and comprises a threaded plug configured to be secured in a portion of said threaded cavity;
A method for 3D printing an object on a support, the object being a collimator or a reflector with at least one wall having a first surface (4, 4') and a second, opposite surface (5, 5'), the wall forming a contour wall surrounding a hollow interior, wherein said first surface (4, 4') faces the hollow interior and is intended to serve as an optical functional surface for light collimation or for light reflection, wherein said method comprises the steps of: moving a printing head along a predefined path in an x-y plane extending parallel to said support, extruding and depositing a track of printing material from a nozzle of said printing head during movement of the printing head along the predefined path, to print one layer of said object, and printing consecutive layers onto each other, thereby forming said wall by printing one track on top of another track, wherein said method further comprises the step of selecting an orientation of the object during printing by defining the predefined path of each layer such that at least a portion of said wall has a tangent non-parallel to a normal of the x-y plane, and wherein, in said portion, said first surface (4, 4') faces away from the support and said second surface (5, 5') faces the support, and wherein a surface smoothness of said first surface (4, 4') intended to serve as an optical functional surface is greater than a surface smoothness of said second surface (5, 5'). moving a printing head along a predefined path in an x-y plane extending parallel to said support, extruding and depositing a track of printing material from a nozzle of said printing head during movement of the printing head along the predefined path, to print one layer of said object, and printing consecutive layers onto each other, thereby forming said wall by printing one track on top of another track, wherein said method further comprises the step of selecting an orientation of the object during printing by defining the predefined path of each layer such that at least a portion of said wall has a tangent non-parallel to a normal of the x-y plane, and wherein, in said portion, said first surface (4, 4') faces away from the support and said second surface (5, 5') faces the support, and wherein a surface smoothness of said first surface (4, 4') intended to serve as an optical functional surface is greater than a surface smoothness of said second surface (5, 5').
A controller for a microscope, the controller being configured to: receive image data representing a wound, the image data comprising multiple images of the wound taken along different directions; determine a line of sight (212, 214) towards a bottom of the wound using the image data comprising; calculating an area of the wound within each image; and determining the line of sight (212, 214) based on the direction corresponding to the image having the wound with the greatest area; and output a control signal for the microscope, the control signal instructing the microscope to align its optical axis with the line of sight (212, 214). receive image data representing a wound, the image data comprising multiple images of the wound taken along different directions; determine a line of sight (212, 214) towards a bottom of the wound using the image data comprising; calculating an area of the wound within each image; and determining the line of sight (212, 214) based on the direction corresponding to the image having the wound with the greatest area; and calculating an area of the wound within each image; and determining the line of sight (212, 214) based on the direction corresponding to the image having the wound with the greatest area; and output a control signal for the microscope, the control signal instructing the microscope to align its optical axis with the line of sight (212, 214).
An assembly comprising one or more host bodies formed from a macromolecule having one or more host groups in the side chains, and one or more guest bodies formed from a macromolecule having one or more guest groups in the side chains, wherein the one or more host bodies and the one or more guest bodies are in contact with each other and form the assembly, wherein the one or more host bodies are a gel of a crosslinked polymer having repeating units represented by the following general formulae and, and the one or more guest bodies are a gel of a crosslinked polymer having repeating units represented by the following general formulae and: wherein X represents a hydroxyl group, C NH 2, or C OH, and n is 1 to 200,000, wherein CD represents α-cyclodextrin, β-cyclodextrin, or γ-cyclodextrin, and m is 1 to 200,000, wherein A represents O or NH, R represents an optionally-substituted alkyl group, or an optionally-substituted aryl group, and 1 is 1 to 200, 000.
An electronic scale comprising a weighing space, which is openable and closable, in which a weighing dish is internally disposed, wherein the weighing space is partitioned into upper and lower spaces with a partition plate and the lower space is configured as a weighing chamber, wherein plate-shaped suspended walls (9a,9b)are attached to said partition plate and are at an upper part of the weighing chamber and adjacent to door (10a, 10b) of the weighing chamber, and have a vertical width, are disposed along opening and closing directions of the adjacent door (10a,10b) and the suspended walls (9a,9b) are disposed so as to be drooped along side edges of the partition plate at the weighing chamber side at the side edges adjacent to the door.
An anti-human CC-chemokine receptor 4 antibody for use in a method for the therapy of human T cell leukemia virus type-1 (HTLV-1, also known as human T lymphotropic virus type-1) associated myelopathy or asymptomatic carriage of HTLV-1, said method comprising reducing HTLV-1 virus-infected cells in HAM patients or asymptomatic HTLV-1 carriers, wherein said anti-human CCR4 antibody includes heavy chain complementarity determining regions (CDRs) 1-3 containing the amino acid sequences represented by each of SEQ ID NOs: 1-3 and light chain CDRs 1-3 containing the amino acid sequences represented by each of SEQ ID NOs: 4-6.
A hybrid polypeptide exhibiting at least two hormonal activities, said polypeptide comprising a first bio-active peptide hormone module covalently linked to at least one additional bio-active peptide hormone module, wherein: the first bio-active peptide hormone is exendin-4 or an analog thereof having at least 50% sequence identity to exendin-4 (SEQ ID NO:66); the at least one additional bio-active peptide hormone module is amylin, an analog thereof having at least 50% sequence identity to amylin (SEQ ID NO:45), or hAmylin - 11,18 Arg-sCT(8- 27)-Amylin (SEQ ID NO:396); the bio-active peptide hormone modules are covalently attached using a glycine linker; the first bio-active peptide hormone is an agonist of the GLP-1 receptor and exhibits the insulin secretion activity of exendin-4; and the at least one additional bio-active peptide hormone exhibits the food intake reduction activity of amylin. the first bio-active peptide hormone is exendin-4 or an analog thereof having at least 50% sequence identity to exendin-4 (SEQ ID NO:66); the at least one additional bio-active peptide hormone module is amylin, an analog thereof having at least 50% sequence identity to amylin (SEQ ID NO:45), or hAmylin - 11,18 Arg-sCT(8- 27)-Amylin (SEQ ID NO:396); the bio-active peptide hormone modules are covalently attached using a glycine linker; the first bio-active peptide hormone is an agonist of the GLP-1 receptor and exhibits the insulin secretion activity of exendin-4; and the at least one additional bio-active peptide hormone exhibits the food intake reduction activity of amylin.
An electrical architecture comprising at least a first power source and a second power source, having respectively a first voltage and a second voltage different from the first voltage, for supplying a plurality of nodal controllers through a power supply network, each of said nodal controllers being provided with at least one output port (21, 22) for connecting thereto an electrical load (41, 42) operating with one of said first and second voltages (V1, V2), wherein: - the power supply network comprises a power line connecting the nodal controllers in a ring to each other and supplying said nodal controllers with electrical power from said at least first and second power sources (11, 12), - each nodal controller is linked to the power line via a bidirectional DC/DC converter, said bidirectional DC/DC converter being configured to convert the voltage (V1, V2) provided by any one of the two power sources (11, 12) in the power line to a voltage (V2, V1) corresponding to the voltage of the other one of the power sources (11, 12), in an operating mode, - the first power source is connected to the power line via a power line segment, and - the second power source is connected to the power line via a power line segment and the bidirectional DC/DC converter of one of the nodal controllers. - the power supply network comprises a power line connecting the nodal controllers in a ring to each other and supplying said nodal controllers with electrical power from said at least first and second power sources (11, 12), - each nodal controller is linked to the power line via a bidirectional DC/DC converter, said bidirectional DC/DC converter being configured to convert the voltage (V1, V2) provided by any one of the two power sources (11, 12) in the power line to a voltage (V2, V1) corresponding to the voltage of the other one of the power sources (11, 12), in an operating mode, - the first power source is connected to the power line via a power line segment, and - the second power source is connected to the power line via a power line segment and the bidirectional DC/DC converter of one of the nodal controllers.
A method comprising, by one or more computing devices: receiving, from a client device of a first user of an online social network, a search query inputted by the first user; determining one or more search terms based on the received search query, each search term comprising a prefix and a suffix, wherein each prefix corresponds to an edge type and an object type of a social graph of the online social network, and wherein each suffix corresponds to a particular node (202, 204) of the social graph; identifying one or more search results matching the search query by applying a suitable hash function to each search term, wherein the suitable hash function is determined based on an object type corresponding to the suffix of each search term; and sending, to the client device of the first user in response to the search query, one or more identified search results. receiving, from a client device of a first user of an online social network, a search query inputted by the first user; determining one or more search terms based on the received search query, each search term comprising a prefix and a suffix, wherein each prefix corresponds to an edge type and an object type of a social graph of the online social network, and wherein each suffix corresponds to a particular node (202, 204) of the social graph; identifying one or more search results matching the search query by applying a suitable hash function to each search term, wherein the suitable hash function is determined based on an object type corresponding to the suffix of each search term; and sending, to the client device of the first user in response to the search query, one or more identified search results.
A method for producing an ammonium tungstate aqueous solution, comprising the steps of: producing a polyacid solution containing poly tungstate ions and Mo-containing polyacid ions; adsorbing said poly tungstate ions to a first anion exchange resin of an anion exchange resin and adsorbing said Mo-containing polyacid ions to a second anion exchange resin of said anion exchange resin by supplying said polyacid solution to said anion exchange resin constituted of said first anion exchange resin and said second anion exchange resin connected to each other, such that said first anion exchange resin is first supplied with said polyacid solution; disconnecting said first anion exchange resin and said second anion exchange resin from each other; and bringing an aqueous solution containing ammonium ions, into contact with said first anion exchange resin after the step of disconnecting. producing a polyacid solution containing poly tungstate ions and Mo-containing polyacid ions; adsorbing said poly tungstate ions to a first anion exchange resin of an anion exchange resin and adsorbing said Mo-containing polyacid ions to a second anion exchange resin of said anion exchange resin by supplying said polyacid solution to said anion exchange resin constituted of said first anion exchange resin and said second anion exchange resin connected to each other, such that said first anion exchange resin is first supplied with said polyacid solution; disconnecting said first anion exchange resin and said second anion exchange resin from each other; and bringing an aqueous solution containing ammonium ions, into contact with said first anion exchange resin after the step of disconnecting.
A liquid pharmaceutical composition comprising: 20 to about 70 mg/mL etanercept (including any biosimilar thereof); 10 to 40 mM buffer system, wherein the buffer system is a phosphate buffer system and/or a citrate buffer system; 20 to 150 mM sodium chloride; 0.5 to 5 wt% sucrose; and either aspartic acid or a combination of lysine and proline; wherein: the liquid pharmaceutical composition has a pH between pH 6.1 and 6.5; the liquid pharmaceutical composition is either free of arginine or comprises arginine in a concentration of at most 0.1 mM; the liquid pharmaceutical composition is either free of sulphur-containing amino acid(s) or comprises sulphur-containing amino acid(s) in a concentration of at most 0.1 mM; the liquid pharmaceutical is either free of nitrogen-containing chelating agent(s) or comprises nitrogen-containing chelating agent(s) in a concentration of at most 0.1 mM; and the liquid pharmaceutical composition containing a combination of lysine and proline contains 3.5 to 4.5 wt% sucrose. 20 to about 70 mg/mL etanercept (including any biosimilar thereof); 10 to 40 mM buffer system, wherein the buffer system is a phosphate buffer system and/or a citrate buffer system; 20 to 150 mM sodium chloride; 0.5 to 5 wt% sucrose; and either aspartic acid or a combination of lysine and proline; the liquid pharmaceutical composition has a pH between pH 6.1 and 6.5; the liquid pharmaceutical composition is either free of arginine or comprises arginine in a concentration of at most 0.1 mM; the liquid pharmaceutical composition is either free of sulphur-containing amino acid(s) or comprises sulphur-containing amino acid(s) in a concentration of at most 0.1 mM; the liquid pharmaceutical is either free of nitrogen-containing chelating agent(s) or comprises nitrogen-containing chelating agent(s) in a concentration of at most 0.1 mM; and the liquid pharmaceutical composition containing a combination of lysine and proline contains 3.5 to 4.5 wt% sucrose.
Polypeptide comprising a first and a second immunoglobulin single variable domain, wherein - said first ISV binds to a first target with an average KD value of between 10 nM and 200 nM as measured by surface plasmon resonance; - said second ISV binds to a second target with an average KD value of between 10 nM and 0.1 pM as measured by surface plasmon resonance; and wherein said first ISV and said second ISV bind to said first target and said second target present on the surface of the same cell, wherein said first target is different from said second target, wherein said second ISV enhances binding of said first ISV, wherein binding by said first ISV inhibits a function of said first target, wherein said first target is chosen from the group consisting of Receptor Tyrosine Kinases (preferably class I), GPCRs, DDR1, Discoidin I (CD167a antigen), DDR2, ErbB-1, C-erbB-2, FGFR-1, FGFR-3, CD135 antigen, CD 117 antigen, Protein tyrosine kinase-1, c-Met, CD148 antigen, C-ret, ROR1, ROR2, Tie-1, Tie-2, CD202b antigen, Trk-A, Trk-B, Trk-C, VEGFR-1, VEGFR-2, VEGFR-3, Notch receptor 1-4, FAS receptor, DR5, DR4, CD47, CX3CR1, CXCR-3, CXCR-4, CXCR-7, Chemokine binding protein 2, and CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11; and said second target is chosen from the group consisting of carcinoembryonic antigen ("CEA"), MART-1, gp100, MAGE-1, HER-2, and Lewis Y antigens, CD123, CD44, CLL-1, CD96, CD47, CD32, CXCR4, Tim-3, CD25, TAG-72, Ep-CAM, PSMA, PSA, GD2, GD3, CD4, CD5, CD19, CD20, CD22, CD33, CD36, CD45, CD52, and CD147; and Cytokine receptors including Interleukin-2 receptor gamma chain (CD132 antigen); Interleukin-10 receptor alpha chain (IL-10R-A); Interleukin-10 receptor beta chain (IL-10R-B); Interleukin-12 receptor beta-1 chain (IL-12R-beta1); Interleukin-12 receptor beta-2 chain (IL-12 receptor beta-2); Interleukin-13 receptor alpha-1 chain (IL-13R-alpha-1) (CD213 al antigen); Interleukin-13 receptor alpha-2 chain (Interleukin-13 binding protein); Interleukin-17 receptor (IL-17 receptor); Interleukin-17B receptor (IL-17B receptor); Interleukin 21 receptor precursor (IL-21R); Interleukin-1 receptor, type I (IL-1R-1) (CD121a); Interleukin-1 receptor, type II (IL-1R-beta) (CDw121b); Interleukin-1 receptor antagonist protein (IL-1ra); Interleukin-2 receptor alpha chain (CD25 antigen); Interleukin-2 receptor beta chain (CD122 antigen); Interleukin-3 receptor alpha chain (IL-3R-alpha) (CD123 antigen). - said first ISV binds to a first target with an average KD value of between 10 nM and 200 nM as measured by surface plasmon resonance; - said second ISV binds to a second target with an average KD value of between 10 nM and 0.1 pM as measured by surface plasmon resonance; and
A personal care composition comprising: from 35% to 90% petrolatum, by weight of the composition, from 20% to 50% of an olfactory composition, by weight of the composition, a gelling agent mixture comprising a gelling agent comprising dibutyl lauroyl glutamide and dibutyl ethylhexanoyl glutamide and a solvent comprising the following structure wherein R1 and R2 can be independently selected from a C1-C4 alkyl group.
System for the distribution, automatic packaging and return of publishing products comprising: - an input module; - a scale; - a division module for portions formed by five conveyor belts: - first conveyor belt; - second pivoting conveyor belt; - third conveyor belt; - fourth conveyor belt; - fifth conveyor belt; - a sorting unit formed from three lines of pivoting sorters each having twelve outputs or boxes: - first line of sorters; - second line of sorters; - third line of sorters; - a central management personal computer; - a programmable logic control system; - a central computer system; wherein it is implemented with the following components in order to perform the daily return function of publishing products: - a sensor positioned between the input module and a scale and capable of recognizing the bar code and thus the publication; - trays positioned in an alternating fashion with respect to the twelve outputs of the first line of sorters; - bins or pallboxes positioned to the side of the system and in correspondence of each of the trays and inside which fall the publications being returned; - a sensor having the function of checking the capacity of the bin or pallbox; - a support plate of the sensor. - an input module; - a scale; - a division module for portions formed by five conveyor belts: - first conveyor belt; - second pivoting conveyor belt; - third conveyor belt; - fourth conveyor belt; - fifth conveyor belt; - first conveyor belt; - second pivoting conveyor belt; - third conveyor belt; - fourth conveyor belt; - fifth conveyor belt; - a sorting unit formed from three lines of pivoting sorters each having twelve outputs or boxes: - first line of sorters; - second line of sorters; - third line of sorters; - first line of sorters; - second line of sorters; - third line of sorters; - a central management personal computer; - a programmable logic control system; - a central computer system; - a sensor positioned between the input module and a scale and capable of recognizing the bar code and thus the publication; - trays positioned in an alternating fashion with respect to the twelve outputs of the first line of sorters; - bins or pallboxes positioned to the side of the system and in correspondence of each of the trays and inside which fall the publications being returned; - a sensor having the function of checking the capacity of the bin or pallbox; - a support plate of the sensor.